Srinivasa Punyala
Psychiatry · Hopewell, VANPI 1891134599
Payments from drug & device makers
Across 708 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$1K
- Lundbeck LLC$1K
- plus $5K from 25 others
What the payments were for
- Food & beverage$12,38999%
- Education$1481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 78 | $1,780 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,300 |
| AbbVie(2 entities) | 103 | $1,183 |
| Johnson & Johnson | 53 | $1,142 |
| Neurocrine Biosciences, Inc. | 59 | $1,050 |
| Lundbeck LLC | 54 | $1,002 |
| Otsuka America Pharmaceutical, Inc. | 52 | $954 |
| Teva Pharmaceuticals USA, Inc. | 58 | $862 |
| Supernus Pharmaceuticals, Inc. | 35 | $776 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $449 |
| Indivior Inc. | 13 | $283 |
| Vanda Pharmaceuticals Inc. | 12 | $274 |
| E.r. Squibb & Sons, L.L.C. | 16 | $263 |
| Axsome Therapeutics, Inc. | 7 | $196 |
| Sunovion Pharmaceuticals Inc. | 10 | $183 |
| Ironshore Pharmaceuticals Inc. | 7 | $126 |
| Eisai Inc. | 8 | $120 |
| Corium, LLC | 4 | $111 |
| Shire North American Group Inc | 6 | $89 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| Tris Pharma Inc | 3 | $52 |
| Avanir Pharmaceuticals, Inc. | 2 | $50 |
| Bausch Health US, LLC | 3 | $45 |
| Almatica Pharma LLC | 2 | $32 |
| Adlon Therapeutics L.p. | 2 | $28 |
| Harmony Biosciences LLC | 1 | $24 |
| Merck | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$268
How this compares
$12,537 in reported general payments places this provider in the 90th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 23 | $292,673 |
| Invega SustennaPaliperidone Palmitate | 70 | $214,834 |
| IngrezzaValbenazine Tosylate | 18 | $137,920 |
| LybalviOlanzapine/Samidorphan Malate | 42 | $106,525 |
| Invega TrinzaPaliperidone Palmitate | 11 | $88,563 |
| VraylarCariprazine Hcl | 59 | $86,377 |
| Abilify MaintenaAripiprazole | 26 | $76,137 |
| AustedoDeutetrabenazine | 14 | $70,433 |
| RexultiBrexpiprazole | 41 | $61,374 |
| AristadaAripiprazole Lauroxil | 12 | $36,178 |
| TrintellixVortioxetine Hydrobromide | 66 | $35,025 |
| Risperdal ConstaRisperidone Microspheres | 20 | $33,194 |
| CaplytaLumateperone Tosylate | 12 | $20,609 |
| Aripiprazole | 213 | $15,874 |
| QelbreeViloxazine Hcl | 14 | $9,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $862 | $363,10537 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $1,142 | $336,591101 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,780 | $142,70354 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,050 | $137,92018 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $954 | $137,51167 claims |
| AbbVieVraylar | $1,183 | $86,37759 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $449 | $35,02566 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,300 | $20,60912 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $776 | $9,90214 claims |
| Eisai Inc.Dayvigo | $120 | $5,68417 claims |
| Almatica Pharma LLCSertraline Hcl | $32 | $2,801317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Hopewell
- Banerje KoduruHopewell$19K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
- Anita ClaytonCharlottesville$356K
- Anita KablingerRoanoke$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.